Astria Therapeutics (NASDAQ:ATXS) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $5.02 and traded as high as $5.93. Astria Therapeutics shares last traded at $5.81, with a volume of 188,854 shares.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wedbush reiterated an "outperform" rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, June 13th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $30.00.

Astria Therapeutics Trading Up 3.4%

The company has a market capitalization of $361.72 million, a PE ratio of -3.43 and a beta of 0.41. The firm has a fifty day moving average of $5.07 and a two-hundred day moving average of $6.07.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, equities analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

Institutional investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics during the 4th quarter valued at about $41,000. Tower Research Capital LLC TRC boosted its holdings in Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 2,766 shares during the period. BNP Paribas Financial Markets purchased a new stake in Astria Therapeutics during the 4th quarter valued at about $50,000. Virtus ETF Advisers LLC purchased a new stake in Astria Therapeutics in the 4th quarter worth approximately $65,000. Finally, GAMMA Investing LLC lifted its holdings in Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after buying an additional 7,971 shares during the period. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.